Delivery Order SPE2DB20D2014-SPE2DB25FC94S
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $3,977.47. This contract represents a firm fixed-price delivery order under a competitive, non-set-aside procurement and is scheduled for completion by July 25, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office and serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $6,100.96. This competitively awarded, firm fixed-price delivery order is not set-aside and is scheduled for completion by August 20, 2025. The award represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, with fulfillment occurring at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $10,076.28. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Myrbetriq ER 50 mg tablets in a 90-count configuration, with a ceiling value of $6,187.69. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) valued at $4,037.23. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $3,853.29 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for Myrbetriq ER 50 mg tablets (90-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 12, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, and represents a child delivery order under a larger contract vehicle. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,999.35 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed price, non-set-aside contract was competitively awarded and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical delivery supporting federal medical supply requirements....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) valued at $47,257.33. This firm fixed-price delivery order, which is not set-aside, represents a competitive procurement of pharmaceutical products for federal medical needs. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This award is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $26,574.02. This competitively awarded, non-set-aside contract reflects a firm fixed-price delivery order with an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for pharmaceutical supply of Myrbetriq ER 50 mg tablets (30-count units) with a ceiling value of $2,383.25. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC94SDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $16,088.68. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by September 9, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Myrbetriq is a neurological and urological medication, consistent with the company's extensive portfolio of brand-name and generic pharmaceuticals, vaccines, and specialized medical supplies delivered through multiple therapeutic domains under the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 9/8/25 |